Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042725 | 0.88 | KDM4E (0.45) | HSD11B1EPHX2KMT2AGAALMNA | |
| SCHEMBL6526551 | 0.88 | ALDH1A1 (0.47) | EPHX2GAAALDH1A1MAPTHTT | |
| SCHEMBL1043958 | 0.85 | EPHX2 (0.48) | TP53EPHX2KMT2AMEN1LMNA | |
| SCHEMBL1044403 | 0.85 | LMNA (0.51) | HSD11B1TP53EPHX2KMT2AMEN1 | |
| SCHEMBL1044863 | 0.83 | HSD11B1 (0.44) | HSD11B1LMNAALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL1042842 | 0.82 | EPHX2 (0.48) | HSD11B1TP53EPHX2KMT2AMEN1 | |
| SCHEMBL1045240 | 0.82 | EPHX2 (0.48) | HSD11B1TP53EPHX2KMT2AMEN1 | |
| SCHEMBL1044751 | 0.82 | HSD11B1 (0.44) | HSD11B1GAALMNAHTTSMN1; SMN2 | |
| SCHEMBL1044408 | 0.81 | HSD11B1 (0.46) | HSD11B1TP53EPHX2KMT2AMEN1 | |
| SCHEMBL1041856 | 0.81 | POLB (0.47) | EPHX2KMT2AMEN1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | claimed |
| EP-2271405-A2 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDORXYSTEROID DEHYDROGENASE-1 | Merck Patent GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009135581-A9 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | claimed |
| WO-2009135581-A2 | NOVEL NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885TP53 3543/4885EPHX2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.